Aprea Therapeutics Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price

summarizeSummary

Aprea Therapeutics, Inc. has received a critical deficiency letter from Nasdaq due to its common stock trading below the minimum $1.00 bid price for 30 consecutive business days. This notice, issued while the company's stock is trading near its 52-week low, highlights significant challenges to its continued listing. While there is a 180-day compliance period, the company's low stock price and small market capitalization make regaining compliance difficult without drastic measures. The potential consideration of a reverse stock split, while a common strategy to boost share price, often signals underlying financial distress and can be viewed negatively by investors, potentially leading to further share price erosion. This event introduces substantial uncertainty and risk, overshadowing any positive developments, such as the early clinical data showcased in the January 9, 2026, corporate presentation.

check_boxKey Events

• Nasdaq Deficiency Notice Received

  Aprea Therapeutics received a letter from Nasdaq on January 23, 2026, notifying the company that its common stock has traded below the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

• 180-Day Compliance Period Initiated

  The company has 180 calendar days, until July 22, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.

• Potential Reverse Stock Split

  Aprea Therapeutics stated its intention to monitor its stock price and may consider available options to regain compliance, including initiating a reverse stock split.

auto_awesomeAnalysis

Aprea Therapeutics, Inc. has received a critical deficiency letter from Nasdaq due to its common stock trading below the minimum $1.00 bid price for 30 consecutive business days. This notice, issued while the company's stock is trading near its 52-week low, highlights significant challenges to its continued listing. While there is a 180-day compliance period, the company's low stock price and small market capitalization make regaining compliance difficult without drastic measures. The potential consideration of a reverse stock split, while a common strategy to boost share price, often signals underlying financial distress and can be viewed negatively by investors, potentially leading to further share price erosion. This event introduces substantial uncertainty and risk, overshadowing any positive developments, such as the early clinical data showcased in the January 9, 2026, corporate presentation.